The somatostatin receptor subtype 2 is expressed on macrophages, an abundant cell type in the atherosclerotic plaque. Visualization of somatostatin receptor subtype 2, for oncologic purposes, is frequently made using the DOTA-derived somatostatin analogs DOTATOC or DOTATATE for PET. We aimed to compare the uptake of the PET tracers 68 Ga-DOTATOC and 64 Cu-DOTATATE in large arteries, in the assessment of atherosclerosis by noninvasive imaging technique, combining PET and CT. Further, the correlation of uptake and cardiovascular risk factors was investigated. Methods: Sixty consecutive patients with neuroendocrine tumors underwent both 68 Ga-DOTATOC and 64 Cu-DOTATATE PET/CT scans, in random order. For each scan, the maximum and mean standardized uptake values (SUVs) were calculated in 5 arterial segments. In addition, the blood-pool-corrected target-to-background ratio was calculated. Uptake of the tracers was correlated with cardiovascular risk factors collected from medical records. Results: We found detectable uptake of both tracers in all arterial segments studied. Uptake of 64 Cu-DOTATATE was significantly higher than 68 Ga-DOTATOC in the vascular regions both when calculated as maximum and mean uptake. There was a significant association between Framingham risk score and the overall maximum uptake of 64 Cu-DOTATATE using SUV (r 5 0.4; P 5 0.004) as well as target-to-background ratio (r 5 0.3; P 5 0.04), whereas no association was found with 68 Ga-DOTATOC. The association of risk factors and maximum SUV of 64 Cu-DOTATATE was found driven by body mass index, smoking, diabetes, and coronary calcium score (P , 0.001, P 5 0.01, P 5 0.005, and P 5 0.03, respectively). Conclusion: In a series of oncologic patients, vascular uptake of 68 Ga-DOTATOC and 64 Cu-DOTATATE was found, with highest uptake of the latter. Uptake of 64 Cu-DOTATATE, but not of 68 Ga-DOTATOC, was correlated with cardiovascular risk factors, suggesting a potential role for 64 Cu-DOTATATE in the assessment of atherosclerosis.